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Acute decrease in net glutamate uptake during energy
deprivation
Abstract
The extracellular glutamate concentration ([glu](o)) rises during cerebral ischemia, reaching levels
capable of inducing delayed neuronal death. The mechanisms underlying this glutamate accumulation
remain controversial. We used N-methyl-D-aspartate receptors on CA3 pyramidal neurons as a
real-time, on-site, glutamate sensor to identify the source of glutamate release in an in vitro model of
ischemia. Using glutamate and L-trans-pyrrolidine-2,4-dicarboxylic acid (tPDC) as substrates and
DL-threo-beta-benzyloxyaspartate (TBOA) as an inhibitor of glutamate transporters, we demonstrate
that energy deprivation decreases net glutamate uptake within 2-3 min and later promotes reverse
glutamate transport. This process accounts for up to 50% of the glutamate accumulation during energy
deprivation. Enhanced action potential-independent vesicular release also contributes to the increase in
[glu](o), by approximately 50%, but only once glutamate uptake is inhibited. These results indicate that
a significant rise in [glu](o) already occurs during the first minutes of energy deprivation and is the
consequence of reduced uptake and increased vesicular and nonvesicular release of glutamate.
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The extracellular glutamate concentration ([glu]o) rises during cere-
bral ischemia, reaching levels capable of inducing delayed neuronal
death. The mechanisms underlying this glutamate accumulation re-
main controversial. We used N-methyl-D-aspartate receptors on CA3
pyramidal neurons as a real-time, on-site, glutamate sensor to iden-
tify the source of glutamate release in an in vitro model of ischemia.
Using glutamate and L-trans-pyrrolidine-2,4-dicarboxylic acid (tPDC)
as substrates and DL-threo-b-benzyloxyaspartate (TBOA) as an inhib-
itor of glutamate transporters, we demonstrate that energy depri-
vation decreases net glutamate uptake within 2–3 min and later
promotes reverse glutamate transport. This process accounts for up
to 50% of the glutamate accumulation during energy deprivation.
Enhanced action potential-independent vesicular release also con-
tributes to the increase in [glu]o, by ’50%, but only once glutamate
uptake is inhibited. These results indicate that a significant rise in
[glu]o already occurs during the first minutes of energy deprivation
and is the consequence of reduced uptake and increased vesicular and
nonvesicular release of glutamate.
During brain ischemia, extracellular glutamate concentration([glu]o) increases, reaching levels that activate the N-methyl-
D-aspartate type of glutamate receptor (NMDAR), thereby causing
neuronal death (1). A number of hypotheses have been advanced
to explain this pathological increase in [glu]o (2, 3). Whereas some
studies suggest that the source of accumulating glutamate is vesic-
ular (synaptic) (4–6), others provide evidence for nonvesicular
mechanisms (7–11).
Previous investigations usually have used biochemical (e.g.,
microdialysis) or radiolabeling techniques to measure excitatory
amino acid concentrations at predefined time points (3, 7–9).
These methods, however, provide low spatial andyor temporal
resolution and offer little information on glutamate levels at the
synaptic cleft, where the receptors mediating excitotoxicity are
located. To detect changes in ambient glutamate levels during
energy deprivation (ED) in real time, we have adopted an
alternative approach in which the NMDARs of neurons under-
going ED are used as high-affinity glutamate sensors (12). This
technique has allowed us to determine the relative contribution
of vesicular and nonvesicular release to the increase in [glu]o
during ED.
Materials and Methods
Organotypic Hippocampal Slice Preparation. Experiments were per-
formed on rat organotypic hippocampal slice cultures. Tissue slices
of 400-mm thickness were prepared from 6-day-old rats and
cultured by means of the roller-tube technique as described pre-
viously (13).
Experimental Conditions. After 12–25 days in vitro, cultures were
transferred to a recording chamber mounted onto the stage of an
upright microscope (Axioscop FS 2; Zeiss), and then they were
superfused with external solution (137 mM Na1y2.7 mM K1y146.2
mM Cl2y2.8 mM Ca21y0.5 mM Mg21y11.6 mM HCO32y0.4 mM
H2PO42y5.6 mM D-glucose) at 29–31°C, pH 7.4. To induce ED,
glucose was replaced with 2 mM 2-deoxyglucose, and 5 mM sodium
cyanide (NaCN) was added (14).
Electrophysiological Recordings. Whole cell patch-clamp record-
ings were obtained from CA3 pyramidal cells (Axopatch 200B
amplifier; Axon Instruments, Foster City, CA) with microelec-
trodes (2–5 MV) filled with 122.5 mM Cs-gluconatey10 mM
Hepesy8 mM NaCly10 mM 1,2-bis(2-aminophenoxy)ethane-
N,N,N9,N9-tetraacetate (BAPTA). Cells were considered ac-
ceptable if the holding current at 140 mV was ,600 pA, with
access resistances from 8 to 16 MV. Experiments to record
miniature excitatory postsynaptic currents (mEPSCs) were per-
formed in the presence of 20 mM D-2-amino-5-phosphonovaleric
acid (DAPV). Changes in input conductance were assessed by
applying 0.4-s voltage commands of 610 mV. L-Glutamate,
NMDA, and L-trans-pyrrolidine-2,4-dicarboxylic acid (tPDC)
were applied locally by pressure-ejection as indicated (Neuro-
Phore; Medical System, Great Neck, NY). Cultures treated with
tetanus toxin (100 ngyml), as well as their respective controls,
were incubated for 3 days in serum-free medium to avoid
nonspecific binding with serum proteins (15). For monopolar
stimulation, current pulses (20–100 mA for 100 ms) were applied
with a tungsten electrode.
Drugs and Chemicals. 1,2,3,4-Tetrahydro-6-nitro-2,3-dioxobenzo-
[f]quinoxaline-7-sulfonamide (NBQX), tPDC, and DAPV were
purchased from Tocris Neuramin (Bristol, U.K.); BAPTA, picro-
toxin, glutamate, and NMDA were purchased from Sigma; and
tetrodotoxin was purchased from Latoxan (Valence, France).
DL-threo-b-benzyloxyaspartate (TBOA) was a gift from K.
Shimamoto (Suntory Institute for Bioorganic Research, Osaka),
and L-644711 was a gift from Merck.
Data Analysis. Signals were filtered at 2 kHz and digitally recorded
on computer by using CLAMPEX 7 (Axon Instruments). Numerical
data are expressed as mean 6 SEM. Student’s t test was used to
compare means. P , 0.05 was considered significant.
Nomenclature. When referring to transporters, ‘‘uptake’’ signifies
unidirectional influx, and ‘‘release’’ signifies unidirectional ef-
f lux of glutamate. ‘‘Net uptake’’ describes the net transport of
glutamate across the membrane, that is, uptake-release.
Results
Changes in [glu]o were detected by monitoring the current flow
through NMDARs on CA3 pyramidal cells in hippocampal slice
cultures (12, 16). For recording NMDAR-mediated responses, cells
were held at 140 mV in the presence of NBQX (25 mM), picrotoxin
(300 mM), and tetrodotoxin (0.5 mM).
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Extracellular Glutamate Rapidly Activates NMDARs During ED. ED
induced an outward current in CA3 pyramidal cells that reached an
amplitude of 218 6 64 pA after 7 min of ED. This response was
reduced by 70 6 5% with application of the NMDAR antagonist
DAPV (100 mM; n 5 17; P , 0.05). DAPV did not induce an inward
current under control (Ctl) conditions (5 6 9 pA; n 5 7; P , 0.05)
(Fig. 1A).
The DAPV-insensitive current displayed a linear current–voltage
(I–V) relationship with a reversal potential close to 0 mV, and may
reflect inhibition of Na1K1 ATPase (17), as application of the
specific antagonist ouabain (5 mM) under Ctl conditions generated
a current with a similar I–V relationship (n 53; data not shown).
The observed NMDAR activation may result from an increase in
[glu]o or reflect an enhancement in NMDAR sensitivity to [glu]o
caused by ED. When brief pulses of NMDA (500 mM in pipette; 80-
to 200-ms duration) were applied close to the recorded neuron,
NMDA responses decreased to 45 6 10% of Ctl responses after 4
min of ED (Ctl, 599 6 30 pA; n 514; P , 0.05) (Fig. 1B), indicating
a decrease in sensitivity of NMDARs during ED. To rule out the
possibility that the decrease of the NMDA transient was caused by
occlusion with ED-mediated NMDAR activation, the effects of
alternating pulses of glutamate (400 mM in pipette 1; 80- to 200-ms
duration) and NMDA (500 mM in pipette 2) were compared during
control conditions and in the presence of TBOA, a nontransport-
able competitive inhibitor of glutamate transporters (12, 18). As
illustrated in Fig. 1C1, extracellular glutamate accumulation in-
duced by TBOA that produced an outward current similar in
amplitude to the one observed during ED failed to reduce the
amplitude of responses to pressure-applied NMDA (n 5 7). In fact,
responses to pressure-applied NMDA remained constant, indicat-
ing that the receptors were not saturated. In addition, consistent
with the block of glutamate uptake, responses to pressure applica-
tion of glutamate were potentiated and greatly exceeded responses
to pressure-applied NMDA (Fig. 1C2) (12).
The DAPV-sensitive current was not significantly different when
ED was induced in the presence of N2 instead of NaCN (N2 1
2-deoxyglucose, 212 6 76 pA after 7 min; n 5 3; P . 0.05; data not
shown). Similar DAPV-sensitive currents during ED also were
observed in CA1 pyramidal cells (CA1, 193 6 44 pA; CA3, 153 6
45 pA after 7 min of ED; n 53; P . 0.05; data not shown).
To test the effect of ED on action potential (AP)-dependent
vesicular release, we evoked NMDAR-mediated EPSCs by stimu-
lating neurons in the CA3 region with an extracellular monopolar
electrode (20–100 mA for 100 ms) in the absence of tetrodotoxin.
During ED, NMDAR EPSCs were depressed to 12 6 4% of Ctl
values after 3 min (Ctl, 163 6 31 pA; n 54; P , 0.05) (Fig. 1D).
Because NMDAR sensitivity is depressed to 50% of Ctl during ED,
this result indicates that evoked glutamate release decreases to
’24% of Ctl values (12%y50%) during ED. Therefore, in agree-
ment with previous data (see refs. 2 and 3 for reviews), these
experiments exclude AP-dependent release as a major source of
glutamate during ED.
Vesicular Release of Glutamate. An elevation in [glu]o may be caused
either by an increase in release or by a decrease in uptake. We first
examined whether AP-independent vesicular release underlies
glutamate accumulation by measuring a-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid (AMPA) receptor-mediated
mEPSCs at 260 mV. The frequency of mEPSCs progressively
increased throughout ED, reaching 10.3 6 3.1 times Ctl values after
7 min (Ctl, 2.9 6 1.6 Hz; n 5 5; P , 0.05) (Fig. 2A). mEPSC
amplitude was not affected (90 6 6% of Ctl after 8 min of ED; P .
0.05; data not shown). To determine whether increased spontane-
ous vesicular release contributes to the increased [glu]o during ED,
slice cultures were incubated with tetanus toxin (TeNT) to inhibit
vesicular fusion (19, 20). In TeNT-treated slice cultures, no
mEPSCs were observed during ED (data not shown), and the
NMDAR-mediated current after 9 min of ED was reduced to 44 6
Fig. 1. NMDARs are activated by [glu]o during ED. (A1) Single trace depicting that ED-induced outward current in CA3 pyramidal cells is decreased by DAPV.
Downward deflections represent responses to 210 mV voltage steps. (Inset) The current–voltage relationship of DAPV-sensitive current displays a negative slope at
hyperpolarized potentials, characteristic of NMDAR currents. (A2) Pooled data; n 5 17. (A3) DAPV reduces the current to 30 6 5% of its initial value. (A4) Under Ctl
conditions, DAPV blocks outward currents induced by glutamate pulses (400 mM in pipette; 150 ms) without affecting baseline holding current. (B1) Single trace
depicting that responses to NMDA pulses decrease during ED. (B2) Pooled data; n 5 14. (C1) An increase in ambient [glu]o is not sufficient to occlude NMDAR-mediated
responses. Time course of the effect of TBOA on baseline holding current and NMDAR-mediated responses to NMPA and glutamate puffs. (C2) Time course of the effect
of TBOA on NMDA and glutamate puffs after subtraction of baseline holding current. (D1) Depression of NMDAR-mediated EPSCs. (D2) Time-course graph. Stimulus
frequency, 0.1 Hz; bin size, six stimuli; n 5 4. DAPV concentration is 100 mM in this and in subsequent figures.
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7% of the value obtained in interleaved control cultures (Ctl, 283 6
23 pA; n 5 9; P , 0.05) (Fig. 2B), suggesting that approximately half
of the [glu]o is of vesicular origin.
To test directly whether enhanced vesicular release can lead to
detectable increases in [glu]o, we artificially stimulated vesicular
release with extracellular sucrose (21). Although sucrose (500 mM
for 2 min) increased the frequency of mEPSCs to the same extent
as did 6 min of ED (sucrose, 3.1 6 0.9 3 Ctl; ED, 5.0 6 1.1 3 Ctl;
n 5 5; P . 0.05), this did not induce an NMDAR-mediated current
(sucrose, 215 6 11; n 5 6) (Fig. 3). However, when glutamate
uptake was inhibited with TBOA (250 mM), application of sucrose
immediately increased [glu]o (152 6 48 pA; n 5 6) (Fig. 3). In slice
cultures treated with TeNT, sucrose did not increase [glu]o in the
presence of TBOA (0 6 23 pA; n 5 5; data not shown). These
results show that an increase in the frequency of AP-independent
vesicular release raises [glu]o only if glutamate uptake is reduced.
We therefore examined whether net glutamate uptake is reduced
during ED.
Impaired Net Glutamate Uptake During ED. The extracellular con-
centration of glutamate after brief local application depends on
transporter function, whereas the concentration of NMDA after a
similar application does not, because NMDA is not transported (12,
22). We therefore measured the relative changes in glutamate
versus NMDA responses to monitor transporter function during
ED. Alternating pulses of glutamate (400 mM in pipette 1; 80 to 200
ms) and NMDA (500 mM in pipette 2) were applied close to the
patched neuron. In agreement with the results in Fig. 1B, NMDA
responses were depressed to about half those of Ctl after 7 min of
ED (NMDA, 48 6 8%). In contrast, glutamate responses only
decreased to 79 6 5% of Ctl (n 5 8; P , 0.05) (Fig. 4A). Both
responses were abolished by DAPV (data not shown). The gluta-
mateyNMDA response ratio increased throughout ED and dou-
bled after 9 min (2.0 6 0.8 3 preED), which could be mimicked by
inhibiting uptake with TBOA (250 mM) (glutamateyNMDA, 6.9 6
2.4 3 preTBOA; n 5 7) (Fig. 4A3). These results indicate that ED
rapidly reduces net glutamate uptake capacity and suggest that
failure of transporters of the EAAT family contributes to the
increase in [glu]o.
Transporter function was further assessed by comparing the
effects of TBOA under Ctl versus ED conditions. We previously
showed that inhibiting glutamate uptake with TBOA under Ctl
conditions causes an increase in [glu]o (12). If net glutamate uptake
is reduced during ED, it should occlude that action of TBOA. In five
experiments, TBOA (250 mM) was applied under Ctl conditions
and again during ED. The NMDAR-mediated current induced by
TBOA during ED was reduced to 6 6 7.5% of that of preED
(preED, 500 6 89 pA; n 5 5; P , 0.05) (Fig. 4B). This reduction
cannot be attributed to desensitization or saturation of NMDARs,
because when compared with Ctl conditions, the depression of
TBOA responses during ED was 8.0 6 2.1 times greater than the
depression of responses to pulses of NMDA in the same cell (n 5
Fig. 2. ED increases AP-independent vesicular release of glutamate. (A1)
Sample traces of AMPA receptor-mediated miniature EPSCs at 260 mV, in the
presence of DAPV and picrotoxin at two different time resolutions. (A2) Time-
course plot of the increase in mEPSC frequency during ED. (A3) Cumulative plot
for interevent intervals. (Inset) Expanded time scale; n 5 5. (B1) Inhibition of
vesicular release with TeNT limits the increase in [glu]o during ED. (B2) Summary
histogram of normalized values of the DAPV-sensitive current after 9 min of ED
for Ctl and TeNT-treated cultures; n 5 9.
Fig. 3. Increased vesicular release is not sufficient to account for increased
[glu]o. (A) (Top) Increasing mEPSC frequency with sucrose under Ctl conditions
induces negligible outward current. (Bottom) After blockade of glutamate up-
take with TBOA, sucrose induces a large NMDAR-mediated outward current
(different cell from above). (B) The frequency of mEPSCs is not significantly
different after 2 min treatment with sucrose or 6 min of ED. Values are normal-
ized to mEPSC frequency during Ctl; n 5 8. (C) Pooled data for the amplitude of
NMDAR-mediated currents induced by sucrose alone and by sucrose in presence
of TBOA; n 5 6.
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5; P , 0.05). These results indicate that net uptake by glutamate
transporters is decreased during ED.
Glutamate Efflux Increases During ED. After prolonged ischemia,
extracellular K1 and intracellular Na1 concentrations rise, altering
the electrochemical gradients driving glutamate uptake. Under
these conditions, glutamate flux through the transporters is pre-
dicted to reverse, increasing glutamate release and consequently
reducing net glutamate uptake (10, 22, 23). We therefore examined
whether the reduction in net uptake during ED described above
could reflect reverse glutamate transport.
Net glutamate release (negative net glutamate uptake) by trans-
porters is seen under two conditions,: (i) reverse transport and (ii)
heteroexchange, where a transporter substrate such as tPDC (24) is
exchanged for intracellular glutamate (25, 26). The glutamate
release step is common to both processes (23, 25) (Fig. 5B).
Therefore, if the conditions prevailing during ED facilitate reverse
glutamate transport, this process will also be associated with an
increase in the release of glutamate by heteroexchange. In the
following experiment, heteroexchange was thus used as a tool to
monitor reverse glutamate transport. When pulses of the trans-
portable uptake inhibitor tPDC (500 mM in pipette; 100 to 500 ms)
were applied close to a patched neuron, we observed fast transient
NMDAR-mediated currents. In contrast, long (’3 s) pulse appli-
cations of the nontransportable inhibitor TBOA at a high concen-
tration (1 mM) were necessary to induce detectable currents (12)
(n 5 8; data not shown). Given that tPDC increased [glu]o at rates
18 times greater than those of TBOA (TBOA mean rising slope,
44 6 7 pAys; tPDC mean rising slope, 804 6 166 pAys; n 5 8; data
not shown), and that tPDC and TBOA have similar affinities for
transporters (18, 25), this finding suggests that tPDC evoked
glutamate release by heteroexchange. When ED was induced, the
amplitude of tPDC-evoked currents progressively increased, reach-
ing 4.9 6 2.1 times the Ctl value after 6 min, (n 5 5; P , 0.05)
(Fig. 5A).
This increase in NMDAR activation may reflect decreased
clearance of tPDC-evoked glutamate release rather than increased
heteroexchange. If this were the case, however, the greater tPDC
response could not exceed the potentiation of the IgluyINMDA
current ratio (Fig. 4A2), because the increase in this ratio reflects
Fig. 4. ED reduces net glutamate uptake. (A1) Brief alternating applications of glutamate and NMDA were used to evaluate the net effect of glutamate transporter
function on glutamate responses. In the sample traces, both responses decrease in amplitude, but the NMDA response is decreased to a greater extent than is the
glutamate response. (Right) Both traces were scaled to the NMDA response amplitude under Ctl conditions. (A2) Pooled data. (Upper) Glutamate responses decrease
less than NMDA responses do. (Lower) The glutamateyNMDA response ratio reveals the time course of the rundown in glutamate transporter function. Applications
were alternated every 15 s. Bin size, four applications; n 5 8. The arrowhead indicates the time when sample traces in A1 were recorded. (A3) Inhibition of glutamate
transporterswithTBOA(250 mM) increases theglutamateyNMDAresponse ratio.Note thatNMDAresponsesareunaffected.Traces showaveragesof threeconsecutive
responses. (B1) TBOA increases [glu]o under Ctl conditions, but its effect is occluded during ED. In the sample trace, upward deflections are responses to 200-ms NMDA
applications. (B2) Illustration of data from individual cells. The open circles denote the cell in A1; the closed circles denote the other four cells tested. (B3) Pooled values;
n 5 5. Note that TBOA responses are depressed by a factor of 8 as compared with NMDA responses.
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a decrease in net uptake during ED. The potentiation of the tPDC
response was about 3 times greater than the IgluyINMDA ratio (490%
vs. 160% after 6 min ED), suggesting that the increase in tPDC
responses reflects a genuine increase in evoked glutamate release
during ED. Thus, conditions promoting net glutamate release
through the transporters progressively develop within a few minutes
of ED.
Discussion
Using NMDARs on CA3 pyramidal cells as a real-time, on-site
sensor to monitor [glu]o, we found that enhanced vesicular release,
in combination with an acute decrease in net glutamate uptake,
produces an increase in [glu]o during ED. These findings indicate
that transporter function is perturbed within a few minutes of ED.
At this time, the massive ionic redistribution that accompanies
anoxic depolarization, recorded as a sudden increase of several
nanoamperes in the holding current (data not shown), has not yet
occurred (27).
NMDAR Activation and Desensitization During ED. NMDAR re-
sponses were reported to be potentiated after ischemia (28). In this
paper, we show that during ED, neuronal responses to puffs of
NMDA decrease by ’50%. This desensitization seems to be
specific for NMDARs, as the amplitude of AMPA receptor-
mediated mEPSCs was not changed during ED and may be
attributable to a decrease in energy-dependent receptor phosphor-
ylation (29), dephosphorylation (30, 31), or increases in extracel-
lular H1, Zn21, or K1 concentrations during ischemia (32–35).
Vesicular Versus Nonvesicular Release. The functional consequences
of the initial increase in AP-independent vesicular release during
ED remain speculative (2, 6, 36, 37). Our experiments with TeNT
indicate that this type of vesicular release is responsible for ’50%
of extracellular glutamate accumulation at the onset of ED. Im-
portantly, by dissociating vesicular release from transporter uptake
with sucrose and TBOA, we show that AP-independent vesicular
release contributes to the increase in [glu]o only when glutamate
uptake is impaired. With prolonged ED, the proportion of gluta-
mate released by vesicular means, however, is likely to decrease
rapidly with progressive ATP depletion (38).
Reverse glutamate transport also contributes to the increase in
[glu]o during ED, because application of TBOA, which blocks (i.e.,
stops the cycling of) transporters, produced an inward current in
three of five cells (26 6 16 pA) (Fig. 4B2), indicating that a source
of glutamate was blocked and that net release was occurring (i.e.,
in these cells, glutamate release by transporters was greater than
was uptake). Other sources of glutamate, such as arachidonic
acid-sensitive release (39) and swelling-activated release (9) are
unlikely to contribute to the TeNT-resistant rise in [glu]o. Indeed,
arachidonic acid-sensitive glutamate release is blocked by TeNT
(39), and L-644711 (1 mM), a specific antagonist of volume-
sensitive Cl2 channels (9), did not reduce NMDAR activation after
7 min of ED (n 5 5; data not shown).
Mechanism of Net Uptake Decrease. Two independent observations
indicate that net glutamate uptake is decreased during ED by
using two independent approaches. First, the glutamateyNMDA
response ratio was increased. This result is independent of the
molecular or pharmacological identification of the transporters,
and reflects the net function of all glutamate uptake systems in
the hippocampal slice culture. Second, the increase in [glu]o
caused by the nontransportable inhibitor TBOA was occluded,
Fig. 5. ED promotes reverse glutamate transport. (A) Glutamate heteroexchange increases during ED. Sample trace showing that brief (300 ms) tPDC applications
induce progressively more release of glutamate during ED. (A2) Pooled data; n 5 7. (B) Glutamate efflux can occur during reverse transport or during heteroexchange.
Pulses of tPDC will shift the transporter into the ‘‘gluy3Na1yH1 inside’’ state. The glutamate binding site is then returned to the outside through transport of either
K1 or glutamate. During ED, the latter pathway (common to heteroexchange and reverse transport) is favored. See Results for details. This figure is adapted from refs.
22 and 24.
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demonstrating the involvement of the EAAT family of trans-
porters.
Net uptake can be reduced as a consequence of decreased uptake
or increased release of glutamate by transporters. The latter
possibility was examined by using tPDC as a substrate to induce
glutamate release by heteroexchange. Using heteroexchange to
monitor reverse transport is justified, because the rate-limiting step
in the transport reaction is thought to be common to both hetero-
exchange and reverse transport (23, 25). We observed an increase
in tPDC heteroexchange during ED, reflecting increased glutamate
release. This increase could result from a rise in intracellular Na1
or glutamate concentrations during ED, both of which increase
heteroexchange and reverse transport (40). In parallel, factors
released during ischemia are known to inhibit glutamate transport-
ers (41–44), which could also contribute to the decrease in net
uptake.
What Is the Concentration of Extracellular Glutamate Attained During
ED? The interstitial glutamate concentration achieved during ED
can be estimated by comparing the desensitization-corrected,
DAPV-sensitive increase in membrane conductance caused by ED
versus a saturating concentration of NMDA at 0 mV (800 mM)
(45–49) as measured with brief voltage steps (400 ms; 15 mV). By
using this protocol, the increase in conductance after 5 min of ED
was ’34% of the increase caused by 800 mM NMDA (DED 5 min-Ctl,
1227 6 25%; DNMDA-Ctl, 1690 6 100%; n 5 7; data not shown),
which, based on concentration-response curves for glutamate-
induced NMDAR activation (EC50 5 1.1 mM; Hill coefficient 5
1.4), corresponds to a glutamate concentration of 650–700 nM (46,
47, 50). After 9 min of ED, this value reaches 900 nM (DED 9 min-Ctl,
1307 6 80%; n 5 6). Thus, after about 10 min of ED, but before
anoxic depolarization, [glu]o in the vicinity of NMDARs is roughly
1 mM, or 500 times the minimal value transporters can maintain
(2 nM) (51). This glutamate concentration, which approximately
corresponds to the EC50 of NMDARs, kills 50% of cerebral cortex
neurons in culture when uptake is inhibited (52).
In conclusion, our results indicate that [glu]o increases during
the early phase of ED because of increased vesicular release,
decreased uptake, and increased reverse transport. Thus, net
uptake is affected even without a massive breakdown in ionic
gradients, suggesting that chronic low-level energy deficits could
also compromise glutamate transport and lead to the patholog-
ical stimulation of glutamate receptors in various neurodegen-
erative diseases (53).
Noted Added in Proof. While this manuscript was under review, similar
findings were reported from a study by Rossi et al. (54).
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